Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Income from Continuing Operations (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Income from Continuing Operations data on record, last reported at 17924000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 2.94% year-over-year to 17924000.0; the TTM value through Sep 2025 reached 64921000.0, up 27.09%, while the annual FY2024 figure was 79305000.0, 55.81% up from the prior year.
  • Income from Continuing Operations reached 17924000.0 in Q3 2025 per BTAI's latest filing, up from 19844000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13463000.0 in Q1 2025 and bottomed at 54866000.0 in Q4 2022.
  • Average Income from Continuing Operations over 4 years is 31665266.67, with a median of 26823000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: tumbled 65.92% in 2023, then surged 62.63% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 54866000.0 in 2022, then soared by 57.3% to 23429000.0 in 2023, then surged by 41.57% to 13690000.0 in 2024, then tumbled by 30.93% to 17924000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 17924000.0 in Q3 2025, 19844000.0 in Q2 2025, and 13463000.0 in Q1 2025.